Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension

被引：8
|
作者：
Koo, Rachel [1 ]
Lo, Jennifer [2 ]
Bock, Matthew J. [2 ]
机构：
[1] Loma Linda Univ Childrens Hlth, Dept Pediat, Loma Linda, CA USA
[2] Loma Linda Univ Childrens Hlth, Div Pediat Cardiol, Loma Linda, CA USA
来源：
CARDIOLOGY IN THE YOUNG | 2019年 / 29卷 / 06期
关键词：
Selexipag; infant; prostacyclin; pulmonary hypertension; paediatric;
D O I：
10.1017/S1047951119001082
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.
引用
下载
收藏
页码：849 / 851
页数：3
相关论文
共 50 条
  • [31] Intravenous treprostinil in pulmonary arterial hypertension: A controlled trial in India
    Wade, Michael
    CHEST, 2007, 132 (04) : 635S - 636S
  • [32] Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension
    Radosevich, John J.
    DeChristopher, Audra
    Irandost, Maykel
    Fann, Jade
    Feldman, Jeremy
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (15) : 1208 - 1212
  • [33] Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension
    Preston, Ioana R.
    Feldman, Jeremy
    White, James
    Franco, Veronica
    Ishizawar, David
    Burger, Charles
    Waxman, Aaron B.
    Hill, Nicholas S.
    PULMONARY CIRCULATION, 2014, 4 (03) : 456 - 461
  • [34] Transitioning from intravenous epoprostenol to subcutaneous treprostinil in stable pulmonary arterial hypertension outpatients
    Lobacz, D
    Harris, K
    Roseigno, H
    Zwicke, DL
    Watson, J
    CHEST, 2004, 126 (04) : 760S - 760S
  • [35] Rapid Inpatient Titration of Intravenous Treprostinil for Severe Pulmonary Arterial Hypertension
    Hansen, L.
    Rischard, F.
    Knoper, S.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S309 - S309
  • [36] Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
    Desole, Susanna
    Richter, Manuel Jonas
    Heine, Alexander
    Ewert, Ralf
    PULMONARY CIRCULATION, 2018, 9 (01)
  • [37] Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension
    Olsson, Karen M.
    Richter, Manuel J.
    Kamp, Jan C.
    Gall, Henning
    Heine, Alexander
    Ghofrani, Hossein-Ardeshir
    Fuge, Jan
    Ewert, Ralf
    Hoeper, Marius M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (07): : 748 - 756
  • [38] Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
    Arevalo, Carlo
    White, R. James
    Lachant, Daniel
    RESPIRATORY MEDICINE CASE REPORTS, 2022, 37
  • [39] Successful Transition From Oral Selexipag to Treprostinil
    Pham, A.
    Techasatian, W.
    Devendra, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [40] One-year experience with intravenous treprostinil for pulmonary arterial hypertension
    Benza, Raymond L.
    Tapson, Victor F.
    Gomberg-Maitland, Mardi
    Poms, Abigail
    Barst, Robyn J.
    McLaughlin, Vallerie V.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2013, 32 (09): : 889 - 896
12345